Literature DB >> 21181139

Lack of effect of hydrochlorothiazide and low-dose aspirin on the renal clearance of urate and oxypurinol after a single dose of allopurinol in normal volunteers.

Daniel Y Ng1, Sophie L Stocker, Garry G Graham, Kenneth M Williams, Richard O Day.   

Abstract

AIMS: To determine whether low-dose aspirin and hydrochlorothiazide (HCTZ) affect the renal clearance of oxypurinol and/or urate.
METHODS: Healthy volunteers (n = 8) were treated with allopurinol (600 mg, control), and allopurinol (600 mg) co-administered with single doses of aspirin (100 mg) or HCTZ (25 mg) or a combination of the two.
RESULTS: Hydrochlorothiazide, low-dose aspirin or a combination of the two, when co-administered with allopurinol, did not significantly alter (P > 0.05) the renal clearance of oxypurinol or urate. In particular, aspirin and HCTZ, when taken together and with allopurinol, did not change (P > 0.05) oxypurinol fractional renal clearance (allopurinol alone: 0.217, 0.173-0.262; combined: 0.202, 0.155-0.250) or urate fractional renal clearance (allopurinol alone: 0.066, 0.032-0.099; combined: 0.058, 0.038-0.078).
CONCLUSIONS: A single, low-dose of aspirin or an anti-hypertensive dose of hydrochlorothiazide, when administered alone or together with allopurinol, are unlikely to alter the hypouricaemic effect of allopurinol. The effect of chronic aspirin and HCTZ dosing taken together upon the efficacy of chronic allopurinol therapy in patients with hyperuricaemia needs to be investigated.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21181139     DOI: 10.1007/s00228-010-0963-6

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  23 in total

1.  Transport properties of nonsteroidal anti-inflammatory drugs by organic anion transporter 1 expressed in Xenopus laevis oocytes.

Authors:  N Apiwattanakul; T Sekine; A Chairoungdua; Y Kanai; N Nakajima; S Sophasan; H Endou
Journal:  Mol Pharmacol       Date:  1999-05       Impact factor: 4.436

2.  Study of the paradoxical effects of salicylate in low, intermediate and high dosage on the renal mechanisms for excretion of urate in man.

Authors:  T F YU; A B GUTMAN
Journal:  J Clin Invest       Date:  1959-08       Impact factor: 14.808

3.  Uric acid retention due to hydrochlorothiazide.

Authors:  L A HEALEY; G J MAGID; J L DECKER
Journal:  N Engl J Med       Date:  1959-12-31       Impact factor: 91.245

4.  Relation between low dose of hydrochlorothiazide, antihypertensive effect and adverse effects.

Authors:  A J Jounela; M Lilja; J Lumme; C Mörlin; A Hoyem; T Wessel-Aas; N J Borrild
Journal:  Blood Press       Date:  1994-07       Impact factor: 2.835

5.  Interactions of human organic anion transporters and human organic cation transporters with nonsteroidal anti-inflammatory drugs.

Authors:  Suparat Khamdang; Michio Takeda; Rie Noshiro; Shinichi Narikawa; Atsushi Enomoto; Naohiko Anzai; Pawinee Piyachaturawat; Hitoshi Endou
Journal:  J Pharmacol Exp Ther       Date:  2002-11       Impact factor: 4.030

6.  Effect of furosemide on renal excretion of oxypurinol and purine bases.

Authors:  T Yamamoto; Y Moriwaki; S Takahashi; Z Tsutsumi; T Hada
Journal:  Metabolism       Date:  2001-02       Impact factor: 8.694

7.  Renal effects of low dose aspirin in elderly patients.

Authors:  Refael Segal; Emilia Lubart; Arthur Leibovitz; Adrian Iaina; Dan Caspi
Journal:  Isr Med Assoc J       Date:  2006-10       Impact factor: 0.892

8.  A double-blind, randomized, placebo-controlled comparison of the metabolic effects of low-dose hydrochlorothiazide and indapamide.

Authors:  W J Elliott; R R Weber; M B Murphy
Journal:  J Clin Pharmacol       Date:  1991-08       Impact factor: 3.126

9.  Kinetics of allopurinol after single intravenous and oral doses. Noninteraction with benzbromarone and hydrochlorothiazide.

Authors:  B Breithaupt; M Tittel
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

10.  Diltiazem compared with hydrochlorothiazide in the treatment of mild-to-moderate essential hypertension.

Authors:  W P Leary; K van der Byl
Journal:  S Afr Med J       Date:  1988-07-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.